Biofrontera Inc Revenue Growth Rates (BFRI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biofrontera Inc   (NASDAQ: BFRI)
 

BFRI's Revenue Growth by Quarter and Year

Biofrontera Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BFRI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 12.00
1st Quarter March 9.87
FY 21.87

BFRIs Annual Revenue
Biofrontera Inc 's Revenue in the fiscal year 2025 $ 84.31 millions
Biofrontera Inc 's Revenue in the fiscal year 2024 $ 76.30 millions
Biofrontera Inc 's Revenue in the fiscal year 2023 $ 81.92 millions
Biofrontera Inc 's Revenue in the fiscal year 2022 $ 73.74 millions
Biofrontera Inc 's Revenue in the fiscal year 2021 $ 11.30 millions




BFRI Revenue second quarter 2026 Y/Y Growth Comment
Biofrontera Inc reported Revenue improvement of 32.92% year on year in the second quarter 2026, to $ 12.00 millions, this is lower than Biofrontera Inc 's recent average Revenue rise of 51.5%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue growth. While Biofrontera Inc ' s Revenue rise of 32.92% ranks overall at the positon no. 685 in the second quarter 2026.


BFRI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 36.15 % 18.49 % -73.46 %
3rd Quarter September - -59.69 % 94.83 % 61.52 %
2nd Quarter June 32.92 % -57.22 % 260.85 % -40.49 %
1st Quarter March 14.9 % -30.61 % -33.01 % 0.11 %
FY   - -34.2 % 44.63 % -

Financial Statements
Biofrontera Inc 's second quarter 2026 Revenue $ 12.00 millions BFRI's Income Statement
Biofrontera Inc 's second quarter 2025 Revenue $ 9.03 millions Quarterly BFRI's Income Statement


BFRI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 144.64 % -27.57 % 19.1 %
3rd Quarter September - -22.59 % -17.86 % 52.14 %
2nd Quarter June 21.61 % 5.12 % 70.52 % -68.34 %
1st Quarter March -42.28 % -31.61 % 16.79 % -53.73 %
FY (Year on Year)   - -34.2 % 44.63 % -


Back to BFRI Growth rate Comparisons >> Back to BFRI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #156
Overall #685

Revenue Y/Y Growth Statistics
High Average Low
335.63 % 51.5 % -73.47 %
(Dec 31 2022)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #156
Overall #685
Revenue Y/Y Growth Statistics
High Average Low
335.63 % 51.5 % -73.47 %
(Dec 31 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biofrontera Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
625.24 % 38.61 % -68.35 %
(Dec 31 2022)  


BFRI's II. Quarter Q/Q Revenue Comment
Biofrontera Inc achieved in the II. Quarter 2026 below company average Revenue jump of 21.61% quarter on quarter, to $ 12.00 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 5.12% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Biofrontera Inc 's Revenue growth quarter on quarter, overall rank is 481.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #96
Overall #481
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #96
Overall #481
Revenue Q/Q Growth Statistics
High Average Low
625.24 % 38.61 % -68.35 %
(Dec 31 2022)  


BFRI's II. Quarter Q/Q Revenue Comment
Biofrontera Inc achieved in the II. Quarter 2026 below company average Revenue jump of 21.61% quarter on quarter, to $ 12.00 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 5.12% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Biofrontera Inc 's Revenue growth quarter on quarter, overall rank is 481.


Biofrontera Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 45.96 $ 42.98 $ 41.71 $ 37.17 $ 47.52
Y / Y Revenue Growth (TTM) -3.29 % -27.88 % -34.21 % -39.5 % -10.31 %
Year on Year Revenue Growth Overall Ranking # 3154 # 2440 # 115 # 685 # 485
Seqeuential Revenue Change (TTM) 6.92 % 3.06 % 12.22 % -21.79 % -20.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 3345 # 2646 # 258 # 2319 # 2652


Cumulative Revenue growth Comment
Biofrontera Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Biofrontera Inc 's annual Revenue fall would be -3.29% year on year to $46 millions.

In the Healthcare sector 422 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2440 to 3154.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 151
Healthcare Sector # 423
Overall # 3154

Revenue TTM Y/Y Growth Statistics
High Average Low
205.95 %
 27.03 %
-48.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 454
S&P 500 # 3345
Cumulative Revenue growth Comment
Biofrontera Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Biofrontera Inc 's annual Revenue drop would be -3.29% year on year to $46 millions.

In the Healthcare sector 422 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2440 to 3154.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 151
Healthcare Sector # 423
Overall # 3154

Revenue TTM Y/Y Growth Statistics
High Average Low
205.95 %
27.03 %
-48.85 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 454
S&P 500 # 3345




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BFRI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions


About Biofrontera Inc Revenue Growth Rates (BFRI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biofrontera Inc (CIK 1858685).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-037834
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biofrontera Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.